Search

• Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint

  Media

  GSK announced a phase III study to assess the efficacy of HZ/su, investigational vaccine for shingles, has met its primary endpoint.

  https://www.gsk.com/en-gb/media/press-releases/pivotal-phase-iii-study-of-gsk-shingles-candidate-vaccine-meets-its-primary-endpoint/

  First published: 18 December 2014

• Results announcement for the third quarter 2015

  Media

  Q3 sees continued progress in execution of Group strategy Sales of £6.1 billion (+11% CER) and core EPS of 23.0p (-13% CER)

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2015/

  First published: 28 October 2015

• 

  General Meeting

  Investors

  Learn more about the announcements and points of discussion during our most recent GSK shareholders’ general meeting

  https://www.gsk.com/en-gb/investors/shareholder-information/general-meeting/

  First published: 07 March 2024

• GSK and Genmab receive EU authorisation for Arzerra

  Media

  GSK & GEN announced today that the EC has granted marketing authorisation for a new indication for the use of Arzerra™ (ofatumumab)...

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-eu-authorisation-for-arzerra/

  First published: 03 July 2014

• GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians’ choice for bulky fludarabine-refractory CLL

  Media

  GSK & GEN announced today that the Phase III study of ofatumumab (Arzerra™) did not meet its primary endpoint of PFS.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-top-line-results-from-a-phase-iii-study-of-ofatumumab-versus-physicians-choice-for-bulky-fludarabine-refractory-cll/

  First published: 27 June 2014

• Results announcement for the fourth quarter 2015

  Media

  GSK delivers further progress with 2015 sales of £24 billion (+6%), core EPS 75.7p (-15%) and total EPS 174.3p, +>100% CER 2016

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2015/

  First published: 03 February 2016

• FDA approves Flonase allergy relief for sale over-the-counter in the United States

  Media

  No. 1 prescribed allergy treatment ingredient1 to be available OTC

  https://www.gsk.com/en-gb/media/press-releases/fda-approves-flonase-allergy-relief-for-sale-over-the-counter-in-the-united-states/

  First published: 24 July 2014

• Regulatory update on three-part transaction with Novartis

  Media

  GlaxoSmithKline plc (GSK) has today received clearance from the European Commission of its proposed three-part transaction with Novartis

  https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-three-part-transaction-with-novartis/

  First published: 28 January 2015

• GSK receives EU marketing authorisation for Incruse (umeclidinium) for the treatment of COPD

  Media

  GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse®

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-eu-marketing-authorisation-for-incruse-umeclidinium-for-the-treatment-of-copd/

  First published: 28 April 2014

• GSK receives positive opinion from the CHMP in Europe for once-weekly EperzanTM (albiglutide) for the treatment of type 2 diabetes

  Media

  GlaxoSmithKline plc today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion albiglutide

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-opinion-from-the-chmp-in-europe-for-once-weekly-eperzantm-albiglutide-for-the-treatment-of-type-2-diabetes/

  First published: 24 January 2014